Success Metrics

Clinical Success Rate
85.6%

Based on 673 completed trials

Completion Rate
86%(673/786)
Active Trials
158(14%)
Results Posted
57%(384 trials)
Terminated
113(10%)

Phase Distribution

Ph not_applicable
65
6%
Ph phase_3
272
24%
Ph phase_4
141
12%
Ph early_phase_1
13
1%
Ph phase_1
147
13%
Ph phase_2
459
41%

Phase Distribution

160

Early Stage

459

Mid Stage

413

Late Stage

Phase Distribution1097 total trials
Early Phase 1First-in-human
13(1.2%)
Phase 1Safety & dosage
147(13.4%)
Phase 2Efficacy & side effects
459(41.8%)
Phase 3Large-scale testing
272(24.8%)
Phase 4Post-market surveillance
141(12.9%)
N/ANon-phased studies
65(5.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.1%

673 of 820 finished

Non-Completion Rate

17.9%

147 ended early

Currently Active

158

trials recruiting

Total Trials

1,129

all time

Status Distribution
Active(180)
Completed(673)
Terminated(147)
Other(129)

Detailed Status

Completed673
unknown127
Terminated113
Recruiting99
Active, not recruiting59
Withdrawn34

Development Timeline

Analytics

Development Status

Total Trials
1129
Active
158
Success Rate
85.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 113 (1.2%)
Phase 1147 (13.4%)
Phase 2459 (41.8%)
Phase 3272 (24.8%)
Phase 4141 (12.9%)
N/A65 (5.9%)

Trials by Status

not_yet_recruiting202%
withdrawn343%
unknown12711%
completed67360%
terminated11310%
enrolling_by_invitation20%
active_not_recruiting595%
recruiting999%
suspended20%

Recent Activity

Clinical Trials (1,129)

Showing 20 of 1,129 trialsScroll for more
NCT05691478Phase 2

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Suspended
NCT03150693Phase 3

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Recruiting
NCT04628767Phase 2

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Recruiting
NCT07856069Phase 2

Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma

Not Yet Recruiting
NCT06124157Phase 2

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
NCT06997068Phase 2

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Recruiting
NCT02981628Phase 2

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT03914625Phase 3

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

Active Not Recruiting
NCT07015242Phase 2

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Recruiting
NCT02203526Phase 1

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

Active Not Recruiting
NCT05279417Phase 2

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

Completed
NCT06317662Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Recruiting
NCT05663866Phase 2

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Active Not Recruiting
NCT07842796Phase 2

Sequential vs. Combined Letrozole and Methotrexate for Tubal Ectopic Pregnancy.

Active Not Recruiting
NCT05600426Phase 3

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Active Not Recruiting
NCT03779854Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Active Not Recruiting
NCT04018937Phase 2

Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

Active Not Recruiting
NCT07176390Phase 2

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

Active Not Recruiting
NCT05645718Phase 2

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Recruiting
NCT02389400Phase 2

Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
1,129